Connect your AI

Opus Genetics IRD Total Equity

Total Equity at other companies

AbbVieABBV

-$6.66B-569%

MeiraGTx Holdings plcMGTX

-$58.13M-276%

4D Molecular TherapeuticsFDMT

$451.84M-3.8%

Opko HealthOPK

$1.2B-8.2%

Kodiak Sciences IncKOD

$112.1M+3.0%

Regeneron PharmaceuticalsREGN

$31.42B+6.9%

Other financials

Income statement

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total assets$66.8M+38.7%

Cash flow

Operating cash flow-$12.7M-41.5%

Valuation

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Opus Genetics's total equity?: Opus Genetics (IRD) reported total equity of -$45.84M in Q1 2026.
How has Opus Genetics's total equity changed year-over-year?: Opus Genetics's total equity decreased by 1003.5% year-over-year, from $5.07M to -$45.84M.
What is the long-term trend for Opus Genetics's total equity?: Over 5 years (2020 to 2025), Opus Genetics's total equity has grown at a 2.6% compound annual growth rate (CAGR), from -$13.47M to $15.35M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.